Irofulven phase 2 application submitted to the Danish Ethics Comitte and Health Care Authorities
Hoersholm, Denmark -- October 27th 2017 – Oncology Venture Sweden AB:s (OV:ST) (“Oncology Venture” or “OV”) announces the filing of the phase 2 protocol of Irofulven for castration- and docetaxel resistant Prostate Cancer has been submitted the Danish Ethics Comitte and Health Care Authorities. The study will include 13-27 patients selected for Irofulven benefit from DRP screened Swedish and Danish patients. The study will be run at two Danish sites – Swedish patients will be refered for Irofulven treatment at the University Hospital in Copenhagen. Using genomic information from the
